



Kala Pharmaceuticals to Present at Partnership Opportunities in Drug Delivery conference

Waltham, Mass., October 4, 2013 – Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Hongming Chen, Sc.D., Kala's Executive Vice President of Research, is scheduled to present at the 3rd Annual Partnership Opportunities in Drug Delivery conference being held October 10-11, 2013 at the Fairmont Copley Plaza in Boston, MA. Dr. Chen's presentation will take place on Thursday, October 10, 2013 at 2:00 p.m. ET during the Drug Delivery Formulation Technologies session.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant unmet needs in both front and back of the eye based on the Company's proprietary Mucus Penetrating Particle (MPP) technology. Kala's topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Kala's product development pipeline includes: a 1% formulation of loteprednol etabonate (1% LE-MPP) to treat post-surgical ocular inflammation and pain, expected to enter a pivotal clinical study in 2014; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, expected to enter clinical trials in 2014, and a topically applied receptor tyrosine kinase inhibitor (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD), which is advancing toward selection of a clinical candidate in 2014.

Kala's approach to penetrating mucus layers also has potential application in other disease areas, such as respiratory, female reproductive tract, and gastrointestinal diseases, and in these areas the Company will seek partners to out-license its breakthrough technology. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, maintains an esteemed group of advisors including co-founder and MIT professor Dr. Robert Langer, and is backed by leading investors including Lux Capital, Polaris Venture Partners, Third Rock Ventures, and Crown Venture Fund, LLC. For more information, please visit www.kalarx.com.

Contact:

Kala Pharmaceuticals, Inc.

Tel: 781 810 4748

info@kalarx.com

Media:

Gina Nugent

The Yates Network

gina@theyatesnetwork.com